Literature DB >> 22516807

Validity of three recently proposed prognostic grading indexes for breast cancer patients with radiosurgically treated brain metastases.

Masaaki Yamamoto1, Takuya Kawabe, Yoshinori Higuchi, Yasunori Sato, Bierta E Barfod, Hidetoshi Kasuya, Yoichi Urakawa.   

Abstract

PURPOSE: We tested the validity of 3 recently proposed prognostic indexes for breast cancer patients with brain metastases (METs) treated radiosurgically. The 3 indexes are Diagnosis-Specific Graded Prognostic Assessment (DS-GPA), New Breast Cancer (NBC)-Recursive Partitioning Analysis (RPA), and our index, sub-classification of RPA class II patients into 3 sub-classes (RPA class II-a, II-b and II-c) based on Karnofsky performance status, tumor number, original tumor status, and non-brain METs. METHODS AND MATERIALS: This was an institutional review board-approved, retrospective cohort study using our database of 269 consecutive female breast cancer patients (mean age, 55 years; range, 26-86 years) who underwent Gamma Knife radiosurgery (GKRS) alone, without whole-brain radiation therapy, for brain METs during the 15-year period between 1996 and 2011. The Kaplan-Meier method was used to estimate the absolute risk of each event.
RESULTS: Kaplan-Meier plots of our patient series showed statistically significant survival differences among patients stratified into 3, 4, or 5 groups based on the 3 systems (P<.001). However, the mean survival time (MST) differences between some pairs of groups failed to reach statistical significance with all 3 systems. Thus, we attempted to regrade our 269 breast cancer patients into 3 groups by modifying our aforementioned index along with the original RPA class I and III, (ie, RPA I+II-a, II-b, and II-c+III). There were statistically significant MST differences among these 3 groups without overlap of 95% confidence intervals (CIs) between any 2 pairs of groups: 18.4 (95% CI = 14.0-29.5) months in I+II-a, 9.2 in II-b (95% CI = 6.8-12.9, P<.001 vs I+II-a) and 5.0 in II-c+III (95% CI = 4.2-6.8, P<.001 vs II-b).
CONCLUSIONS: As none of the new grading systems, DS-GPS, BC-RPA and our system, was applicable to our set of radiosurgically treated patients for comparing survivals after GKRS, we slightly modified our system for breast cancer patients.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22516807     DOI: 10.1016/j.ijrobp.2012.02.040

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  4 in total

1.  Predictors of Lung Adenocarcinoma With Leptomeningeal Metastases: A 2022 Targeted-Therapy-Assisted molGPA Model.

Authors:  Milan Zhang; Jiayi Tong; Weifeng Ma; Chongliang Luo; Huiqin Liu; Yushu Jiang; Lingzhi Qin; Xiaojuan Wang; Lipin Yuan; Jiewen Zhang; Fuhua Peng; Yong Chen; Wei Li; Ying Jiang
Journal:  Front Oncol       Date:  2022-06-10       Impact factor: 5.738

2.  Validity of two recently-proposed prognostic grading indices for lung, gastro-intestinal, breast and renal cell cancer patients with radiosurgically-treated brain metastases.

Authors:  Masaaki Yamamoto; Toru Serizawa; Yasunori Sato; Takuya Kawabe; Yoshinori Higuchi; Osamu Nagano; Bierta E Barfod; Junichi Ono; Hidetoshi Kasuya; Yoichi Urakawa
Journal:  J Neurooncol       Date:  2012-12-09       Impact factor: 4.130

3.  A case-matched study of stereotactic radiosurgery for patients with brain metastases: comparing treatment results for those with versus without neurological symptoms.

Authors:  Takao Koiso; Masaaki Yamamoto; Takuya Kawabe; Shinya Watanabe; Yasunori Sato; Yoshinori Higuchi; Tetsuya Yamamoto; Akira Matsumura; Hidetoshi Kasuya; Bierta E Barfod
Journal:  J Neurooncol       Date:  2016-09-03       Impact factor: 4.130

4.  Prognostic value of cancer antigen -125 for lung adenocarcinoma patients with brain metastasis: A random survival forest prognostic model.

Authors:  Hao Wang; Liuhai Shen; Jianhua Geng; Yitian Wu; Huan Xiao; Fan Zhang; Hongwei Si
Journal:  Sci Rep       Date:  2018-04-04       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.